Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCLEROLYM: Autologous CD4+ T Cells in RRMS
NCT02427776Phase 2Terminated
- Sponsor
- Imcyse
- Start
- Jan 2015
- Primary completion
- Aug 2016
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of MOG-stimulated autologous CD4+ T cells in relapsing-remitting multiple sclerosis (RRMS), sponsored by Imcyse. Started Jan 2015; status: terminated.
02
Drugs
MOG-stimulated autologous CD4+ T cells
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT02427776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02427776.